A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely

AHS Cancer Control Alberta

Status

Unknown

Conditions

Colonic Neoplasms

Neoplasm Metastasis

Treatments

Radiation: Stereotactic Body Radiation Therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT03175146

CRC L-SBRT 15-01

Details and patient eligibility

About

The proposed study will evaluate if "curative intent" SBRT can provide high response rates and clinically meaningful cancer control with acceptable toxicity specifically in patient with metastatic colorectal cancer (mCRC) who do not have surgical options and are no longer responding to systemic therapy

Full description

SBRT for Oligo-metastatic Colorectal cancer

Enrollment

30 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pathologically confirmed Colo-rectal Cancer
1-3 Liver metastasis measurable on Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)
Surgically resected primary disease
Technically/medically inoperable or patient declined surgery
Progression or Stability after at least 1 Line of chemotherapy
Adequate marrow function: Hb > 80g/L, Platelets > 100 x 109/L, White blood cell > 2 x 109/L
Eastern Cooperative Oncology Group (ECOG) status 0-2
Age > 18 years
Patient must sign study specific informed consent prior to study entry

Exclusion criteria

Prior liver radiation, or radiation in close proximity to planned treatment sites
Prior invasive malignancy
Severe, active co-morbidity
Active hepatitis or Child Pugh Score B (9) or worse
Pregnant or nursing women
Extra hepatic disease: Any Bone/Any Brain, 2 or more Lung metastasis
Life expectancy < 6 mo from any cause
Concurrent chemotherapy
Response to prior chemotherapy with minimal measurable disease in liver